0
Editorial |

Treating Anemia With Erythropoiesis-Stimulating Agents:  Effects on Quality of Life

Shahriar Moossavi, MD, PhD; Barry I. Freedman, MD
Arch Intern Med. 2009;169(12):1100-1101. doi:10.1001/archinternmed.2009.159.
Text Size: A A A
Published online

Extract

Isolation and cloning of the human erythropoietin gene resulted in injectable forms of erythropoiesis-stimulating agents (ESAs) suitable for pharmacological use. This breakthrough transformed the lives of millions of individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. The severity and prevalence of anemia are closely associated with kidney dysfunction; the frequency of anemia increases from 27% to 76% with a decline in glomerular filtration rate1 from more than 60 mL/min/1.73 m2 to less than 15 mL/min/1.73 m2. Prior to ESAs, dialysis-associated anemia was typically treated with regular blood transfusions and anabolic steroids.2 Iron overload commonly resulted, and treated patients often had hemoglobin (Hb) concentrations lower than 10 g/dL (to convert to grams per liter, multiply by 10.0). Erythropoiesis-stimulating agents currently available in the United States include epoetin alfa and darbepoetin alfa, and their differential carbohydrate content determines plasma half-life and dosing interval.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
[Use of erythropoiesis stimulating agents.] Rev Mal Respir 2014;31(2):162-172.
Questionnaire-based survey on chemotherapy-induced anemia. Int J Clin Oncol Published online Mar 8, 2014.;
Jobs
brightcove.createExperiences();